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Abstract
BACKGROUND: The aim of the present work was to investigate 
the influence of lithium carbonate on the kinetics of radioiodine 
in the thyroid gland, and the long-lasting effect of radioiodine 
therapy pre-treated with lithium carbonate in patients with dif-
ferent types of hyperthyreosis and low baseline 24-h thyroidal 
radioactive iodine uptake (RAIU).
MATERIAL AND METHODS: The examinations were performed 
in two groups of patients: in a control group with RAIU > 30% 
and in patients with RAIU < 30%. All groups were comparable 
with regard to age, sex, duration and type of disease (Graves’ 
disease, autonomous node, multinodular goitre). The control 
group was treated (without lithium) according to described 
protocol. The second group was pre-treated with lithium car-
bonate in a dose of 1.0 g/day for 6 days before radioiodine and 
3 days thereafter. 
RESULTS: A significant increase in iodide uptake in the thyroid 
gland was observed during intake of lithium carbonate in 106 
out of 128 patients. A decrease of T3, FT3, T4, and FT4 levels 
and no significant changes in concentration of TSH were ob-
served as an effect of lithium carbonate treatment. Three years 
of follow-up show that the results of radioiodine therapy with 
short lasting lithium carbonate intake are better in the first year 
and are similar in the second and third years in comparison to 
the control group. 
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Introduction
Radioiodine has been used in the treatment of thyrotoxico-
sis for almost 60 years [1] and is still used as the method of choice 
in several types of thyroid diseases [2]. 
The dose of radioactivity given to a patient is calculated 
according to a dosimetric formula [2]. Patients with low RAIU 
should be treated with significantly higher activities to obtain 
similar therapeutic effects, or other therapeutic options should 
be considered. 
Lithium salts significantly change the iodine kinetic in thyroid 
tissue through the inhibition of the release of organic iodine from 
the thyroid gland [3–6]. This effect suggests that lithium may be 
useful as an adjunct to radioiodine therapy in thyrotoxicosis. 
The aim of this work was to evaluate whether lithium carbon-
ate pre-treatment will change the iodine uptake in hyperthyroid 
patients with initially low RAIU. We assumed that lithium carbonate 
pre-treatment increases iodine retention; therefore, patients with 
low baseline RAIU can be treated successfully with lowered risk 
of radiation. Our results, as we will show, suggest that lithium 
carbonate pre-treatment in patients with RAIU < 30% is an ef-
fective and profitable method of treatment, independent of the 
type of disease. 
Material and methods
A total of 256 patients with newly diagnosed hyperthyre-
osis were enrolled over four years. All patients were older than 
20 years of age, and the diagnosis of hyperthyroidism was made 
in the preceding 6 months. Patients with previous treatment of 
hyperthyroidism with radioiodine or surgery or with contraindica-
tions to lithium treatment were excluded. 
Patients were treated with methimazole for 2–3 months to 
restore euthyroidism. Methimazole was withdrawn 15 days before 
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examinations and then radioiodine uptake in the thyroid gland 
was measured. Hyperthyroid patients (Graves’ disease, multi-
nodular goitre and autonomous tumour) were divided into two 
groups according to the baseline 24-hour RAIU: higher or lower 
than 30%. Both groups were matched according to the type and 
duration of the disease, age, and sex as possible factors influenc-
ing the results. All patients gave informed consent.
In order to evaluate if the effect of lithium carbonate on radioio-
dine kinetic is dependent of baseline iodine uptake, we examined 
additionally ten hyperthyroid patients with RAIU > 30% before and 
during lithium treatment. 
A total of 128 patients had low RAIU (Group I). In this group 
kinetic examinations of iodine uptake were repeated after lithium 
carbonate was included at a dose of 1.0 g per day (2 × 0.5 g). Lith-
ium carbonate was added 3 days before the start of iodine kinetic 
examinations and was continued until the fifth day. When lithium 
carbonate pre-treatment caused an increase in RAIU a therapeutic 
dose of radioiodine was calculated and implemented. Lithium 
carbonate was given for an additional five days after application 
of the therapeutic dose of 131I. 
In 45% of patients (n = 51) in this group we were able to make 
a three-year systematic observation after 131I treatment.
The other 128 patients with RAIU > 30% (Group II) followed 
the same protocol but without lithium carbonate pre-treatment. 
Iodide uptake was measured over five days. At the end of 
the kinetic studies the therapeutic dose of 131I was calculated 
and given. From this cohort 51 patients (as a randomised control 
group) were also systematically observed over a 3-year period.
The therapeutic dose of radioiodine was calculated according 
to a dosimetric formula [2].
The radiation dose in each type of disease was similar in 
both groups: in Graves’ disease — 80 Gy, in multinodular goitre 
— 200 Gy, and in autonomous tumour — 400 Gy. The mean dose 
of radioiodine in the omised control group was 580 MBq (290–830 
MBq) and in the lithium treatment group 650 MBq (325–900 MBq). 
Table 1 shows the number of patients and type of disease when 
the kinetic of radioiodine was measured, and Table 2 presents the 
number of patients, radioiodine therapeutic dose, and the type of 
disease in whom the effect of therapy was analysed. 
Baseline evaluations included: clinical examination, thyroid 
scan, thyroid uptake of radioiodine after 6, 24, 48, 72, 96, and 
120 hours, thyroid ultrasonography, white cell count, differential 
count, haematocrit, mean corpuscular volume, platelet count, 
creatine, serum electrolytes, urinary analysis, and electrocardio-
gram. Serum total and free T4 (FT4), T3 (FT3), and TSH levels were 
measured. The normal ranges were: serum T4, 55–160 nmol/l; FT4, 
8.4–23.2 pmol/l; T3, 1.3–3.0 nmol/l; FT3, 3.8–8.4 pmol/l; and TSH, 
0.4–3.7 mU/l. The measurements were performed at the beginning 
of lithium carbonate application, immediately before iodine treat-
ment (fifth day of lithium carbonate treatment), 7 and 14 days post 
radioiodine application, and then every 1-3 months for the whole 
of the follow-up period.
The concentrations of lithium carbonate in the serum were 
evaluated on the fifth day of treatment, and it was between 0.6 
and 0.9 (0.8 ± 0.062) mEq/l. Thyroid volume was determined by 
ultrasound using a 7.5 MHz linear transducer and calculated by 
the ellipse model.
The clinical state of the patients was defined during each 
control visit and summarized every year after the treatment. 
Statistical analysis
Baseline values were expressed as mean ± SD for quantita-
tive variables. The baseline characteristics of the two groups were 
compared by unpaired t-test and by one-way analysis of variance. 
Bartlett test equality in variance was performed. All data were 
evaluated using the Stat-Graphics program. 
Table 1. Baseline characteristics of patient study groups with hyperthyroidism in which iodine kinetic was evaluated
Type of disease Graves’ disease multinodular goitre autonomous tumour
 Control Lithium Control Lithium Control Lithium
No of patients 18 18 53 53 46 46
Mean age 62.2 59,9 51.4 53.2 56.3 58.2
Sex m/f 2/16 2/16 9/44 9/44 12/34 12/34
Table 2. Baseline characteristics of the patient study groups observed over 3 years after radioiodine treatment 
Type of disease Graves’ disease multinodular goitre autonomous tumour 
 Control Lithium Control Lithium Control Lithium
No. of patients 18 18 18 18 19 19
Mean age 58.4 57.1 50.2 51.4 53.2 55.1
Sex m/f 2/16 2/16 5/13 5/13 7/12 7/12
Radiation dose (Gy) 80 80 200 200 400 400
Therapeutic 260–470 260–540 480–925 480–925 630–800 600–925
Activity (MBq)
Mean ± SD 120 145 150 165 205 215
SD — standard deviation
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Results
There were no significant differences in the baseline clinical 
and biochemical characteristics between both study groups.
Radioiodine uptake before lithium intake
Table 3 presents the values of radioiodine uptake at different 
times of examination, respectively, in the group of patients with 
low RAIU and in the control group. The uptake of iodine in Group 
I at 6 and 24 hours was on average two-times lower compared 
with the control group. There were no statistically significant differ-
ences between the studied groups in effective and biological half 
life time for radioiodine. Calculated effective half-life times were: 
6.5 ± 0.9 and 6.3 ± 0.7 days, respectively, and biological half-life 
times were 26 ± 1.9 days and 23 ± 1.5 days, respectively. 
Kinetic of iodine during lithium carbonate 
application
In all ten patients with RAIU > 30% in whom the effect of lithium 
carbonate was separately studied, no effect of lithium carbonate 
pre-treatment on radioiodine uptake was noted. The baseline 
uptakes after 6 and 24 hours were 31 ± 6% and 43 ± 4.6%, re-
spectively, and during lithium treatment 32 ± 8% and 41 ± 6.7%, 
respectively. Despite this increases in biological and effective 
half-life times were observed: biological half-life time increased 
from 22 ± 12 days to 211 ± 15 days, and effective half-life time 
from 5.9 ± 2 days to 7.1 ± 1.6 days. There were three patients with 
Graves’ disease, three patients with multinodular goitre, and four 
patients with autonomous tumour.
When lithium carbonate was given to the patients with low 
RAIU, two types of response were noted. 
First, in 22 patients we did not observe any effect of lithium 
carbonate treatment (1 with Graves’ disease, 11 with multinodular 
goitre, and 10 with autonomous adenoma). The baseline up-
takes of iodine after 6 and 24 hours were 7 ± 3% and 19 ± 6%, 
respectively, and during lithium carbonate intakes were 8 ± 4% 
and 19 ± 7%, respectively. Despite this lack of response on 
RAIU, a significant prolongation of the biological and effective 
half-life times were observed. The biological half-life time in-
creased to 240 ± 14 days and effective half-life time to 7.8 ± 0.5 
days (p < 0.005). On the basis of clinical history, incidences of 
iodine overloading were documented 8–20 months before ex-
aminations in all cases.
Second, a significant increase in iodine retention was noted in 
106 patients (p< 0.001). The biological half-life time increased to 
267 ± 24 days (p < 0.001) and effective half-life time to 7.8 ± 0.8 
days (p < 0.001). An analysis of iodine uptake in response to the 
lithium carbonate treatment and correlation with type of disease 
was performed (Table 4).
The increase in RAIU was significantly higher in the group 
of patients with Graves’ disease and autonomous adenoma in 
comparison to the patients with multinodular goitre (p < 0.05).
The effect of lithium treatment on the level 
of thyroid hormones 
Our results (in the group of 128 patients) show that lithium 
carbonate influenced the T3 and T4 plasma levels (p < 0.001) 
as well as FT3 and FT4 levels (p < 0.005) in the initial five-day 
period of treatment. 
No effect of lithium carbonate on the level of TSH in the pre-
sented group was seen (Table 5). 
The level of T4 decreased significantly on the fifth day of lithium 
carbonate treatment, on average, by 10% and T3 by 40%. FT4 de-
creased, on average, by 33% and FT3 by 9%. The beneficial effect 
of lithium carbonate on the thyroid hormones was also observed 
Table 3. RAIU of radioiodine in the studied group
Type of disease Graves’ disease multinodular goitre autonomous tumour
 Control Lithium Control Lithium Control Lithium
T6 4% ± 3.2 28% ± 6.3 11% ± 2.1 34% ± 7.1 12% ± 2.4 30% ± 5.2
T24 26% ± 4.1 50% ± 5.2 24% ± 3.3 54% ± 6.6 25% ± 4.8 57% ± 6.4
T48 26% ± 3.8 48% ± 6.1 26% ± 4.1 50% ± 5.9 26% ± 4.2 54% ± 5.9
T72 24% ± 2.8 45% ± 5.1 24% ± 3.7 45% ± 4.8 25% ± 4.2 50% ± 5.6
T96 24% ± 2.4 40% ± 4.7 24% ± 3.5 43% ± 4.6 24% ± 4.2 47% ± 5.5
Table 4. Iodine uptake before and during lithium carbonate treatment in responded group of patients in different types of hyperthyreosis
Type of disease Graves’ disease multinodular goitre autonomous tumour
Lithium intake Before During Before During Before During
No. of patients 22 22 45 45 39 39
T6 14 ± 2.9 23 ± 4.2 11 ± 2.1 19 ± 2.4 12 ± 3.1 22 ± 3.8
T24 26 ± 3.9 41 ± 5.1 24 ± 1.9 35 ± 2.3 25 ± 2.8 41 ± 3.4
T48 26 ± 3.7 38 ± 4.8 26 ± 2.0 36 ± 2.4 26 ± 3.1 4.2 ± 3.3
T78 24 ± 3.7 37 ± 4.5 24 ± 2.3 34 ± 2.1 25 ± 2.7 41 ± 2.9
T96 24 ± 3.9 35 ± 4.3 24 ± 2.4 33 ± 2.0 24 ± 2.5 39 ± 3.1
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after radioiodine application. There was no change in thyroid 
hormone levels in the control group during this period (Table 6). 
Long-term therapeutic effects of radioiodine 
treatment
A significantly better outcome was noted in the first group of 
patients one year after therapeutic radioiodine application. 
The euthyreosis was observed in 84%, hypothyreosis in 4%, 
and hyperthyreosis in 12% of patients in the group treated by 
lithium carbonate. In the control group 50% of patients were eu-
thyroid, 10% hypothyroid, and 40% hyperthyroid (p < 0.05). In the 
second and third years after treatment the results were comparable 
in both groups. There was no relation between efficiency of the 
lithium carbonate pre-treatment and the type of disease (Table 7).
Discussion
In the present study we evaluated the effect of lithium carbon-
ate on 131I retention in the thyroid gland, on thyroid hormone levels, 
and the late effects of 131I treatment in hyperthyroid patients with 
decreased baseline RAIU in different types of hyperthyreosis. The 
effect of lithium carbonate pre-treatment was documented on the 
basis of three years of observations. 
We recommend this method as a useful tool in this group of 
patients. 
The results show several beneficial effects of lithium carbonate 
pre-treatment in most patients with low baseline RAIU: 
—  a significant increase in radioiodine retention;
—  faster stabilization of the thyroid hormones;
—  significantly better clinical outcome after the first year and 
similar therapeutic effect during the second and third years of 
observation after radioiodine treatment.
The beneficial effect of lithium carbonate as an adjunct to 
the radioiodine treatment in benign thyroid diseases has been 
reported previously by others [3–6], but the number of observed 
patients was relatively small or the period of clinical observation 
was relatively short. This effect was also observed in thyroid 
cancer [7–10]. 
The effect of lithium carbonate on RAIU
Our results show that lithium treatment could produce diffe-
rent effects on radioiodine accumulation in the thyroid gland: in 
patients with RAIU > 30% no effect of lithium carbonate on radio-
iodine uptake in the thyroid gland was noted. In patients with low 
baseline RAIU the effect of lithium carbonate was inhomogeneous: 
in most patients it produced a significant increase of iodine uptake 
but in 17% of cases no effect of lithium carbonate on RAIU was ob-
served. All non-respondents to the lithium carbonate with low RAIU 
had a well-documented history of iodine overloading in the last 
8–20 months before examination. It seems that this is a possible 
factor responsible for the lack effect of lithium salts on RAIU in 
some patients with decreased baseline uptake of radioiodine.
Different effects of lithium carbonate on iodine uptake are 
described in the literature [4, 11–14]. Taken together, the latest 
Table 5. The level of thyroid hormones during lithium carbonate and radioiodine treatment
Time T4 FT4 T3 FT3 TSH 
 [nmol/l] [pmol/l] [nmol/l] [pmol/l] [mU/l]
Before treatment 120 ± 12 25.2 ± 4.1 2.5 ± 0.4 7.5 ± 0.5 0.15 ± 0.03
5th day of Lithium 108 ± 9.2 19.5 ± 2.8 1.5 ± 0.3 6.7±0.5 0.20 ± 0.02
7th day after 131I application 98 ± 9.3 16.7 ± 4.2 1.3±0.2 6.5±0.3 0.12 ± 0.03
14th day after 131I application 92 ± 10.2 14.0 ± 1.1 1.1 ± 0.3 6.5 ± 0.3 0.12 ± 0.03
Table 6. The level of thyroid hormones after radioiodine treatment in the control group
Time T4 FT4 T3 FT3 TSH 
 [nmol/l] [pmol/l] [nmol/l] [pmol/l] [mU/l]
Before treatment 126 ± 15 26.4 ± 3.8 2.3 ± 0.4 7.1 ± 0.4 0.11 ± 0.04
7th day after 131I application 124 ± 10 23.8 ± 0.3 2.3 ± 0.2 7.3 ± 0.3 0.12 ± 0.03
14th day after 131I application 125 ± 12 25.2 ± 0.4 2.1 ± 0.3 6.8 ± 0.3 0.12 ± 0.03
Table 7. Effectiveness of 131I treatment in the control group and in the lithium carbonate pre-treated group
 1st year 2nd year 3rd year 
 Control Lithium Control Lithium Control Lithium
Euthyreosis 25 (50%) 42 (84%) 37 (74%) 42 (84%) 34 (68%) 37 (74%) 
Hyperthyreosis 20 (40%) 6 (12%) 5 (10%) 2 (4%) 2 (4%) 0
Hypothyreosis 5 (10%) 2 (4%) 8 (16%) 6 (12%) 13 (28%) 13 (26%)
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and our results, it seems that the effect of lithium carbonate on 
radioiodine uptake was dependent on different characteristics of 
the examined groups: duration or dose of lithium treatment and 
especially on baseline level of RAIU.
Our results confirm previous observations that lithium carbon-
ate is able to slow the release of iodide from the thyroid [5, 14, 15]. 
Biological and effective half-life times were increased significantly 
and independently of the effect of lithium carbonate on the iodine 
uptake. Similar results have been reported by others [11, 12]. 
This effect, as described previously, is probably caused by 
lithium action on tyreoglobulin [12, 16, 17]. It was concluded [5, 
10] that this mechanism is responsible for the beneficial effect of 
lithium carbonate on the 131I treatment.
The effect of lithium carbonate on thyroid hormone 
levels
Our results show that short-term lithium carbonate treatment 
influenced the dynamic of T3 and T4 concentrations in the serum 
as compared with the control group. Therefore, we suggest that 
lithium pre-treatment is a useful adjunct to radioiodine therapy to 
achieve more effective control of hyperthyroidism. The effect of 
lithium carbonate on thyroid hormones level was previously noted 
by others [6, 16]. Our results show that this effect is not only pre-
sented in patients with Graves’ disease; it was also observed in 
patients with autonomous tumour and multinodular goitre.
No effect of short lithium carbonate treatment on the serum 
TSH level was observed in this study. Similar data have been 
described by others [6, 15]. Our results show that this effect 
is not dependent on the type of hyperthyreosis. The lack of in-
crease in TSH is specially valuable in the use of lithium carbonate 
pre-treatment. It seems that lithium carbonate treatment does not 
provoke an increase in radioiodine uptake via TSH mechanism 
in the peritumoral tissue. It is not possible to exclude direct ac-
tion of lithium ions on normal thyroid tissue, which can provoke 
an increase in iodine accumulation in normal follicular cells, but in 
our opinion this mechanism is not crucial from a clinical point of 
view in these groups of patients; the number of hypothyroid pa-
tients with autonomous tumour or multinodular goitre after lithium 
pre-treatment was lower in the first year after radioiodine treatment.
Lithium carbonate and the late effects 
of radioiodine treatment
The results confirmed a beneficial effect of lithium treatment 
on radioiodine therapy in the group of patients with low baseline 
accumulation of iodide, compared to the control group with normal 
iodide uptake. The effect was statistically significant in the first 
year after radioiodine application and similar to the control group 
in the second and third years of observation. Our results are in 
accordance with the data of Brownline et al. [18], who concluded 
that the addition of lithium to radioiodine did not produce a higher 
rate of cure after three years of follow-up.
In both examined groups of patients therapeutic doses of 
radioiodine were estimated according to a dosimetric formula, 
which is based on the absorbed radiation dose. It meant that both 
groups of patients were given similar radiation doses with respect 
to the disease. Until now, all observations concerning the beneficial 
effects of lithium on radioiodine treatment have been analysed in 
patients when the therapeutic activity of the radioiodine was based 
on the fixed-dose method [14] or MBq per gram of thyroid tissue 
[6]. None of these methods was able to define the exact absorbed 
dose of radioactivity as a true dosimetric qualitative parameter of 
the effect of ionising rays.
The improved long-term results of radioiodine treatment in the 
group of patients in which lithium carbonate was given (despite similar 
absorbed dose) suggest that the mechanism of the lithium effect 
is dependent not only on prolongation of iodide decrease from the thy-
roid gland or increase in radioiodine retention; we suggest that other 
mechanisms can be responsible for the beneficial effect of lithium.
Our results show that the use of lithium carbonate enabled 
significantly lower doses of radioactivity to be used in patients with 
low baseline uptake of radioiodine in comparison with the calcu-
lated dose before lithium carbonate pre-treatment, not only in 
Graves’ disease but also in other types of thyroid disease. The 
radioactivity given to a patient with diminished based RAIU can 
be reduced during lithium carbonate pre-treatment by about 
80–100%. It is particularly beneficial in young patients in whom the 
total body-radiation dose must be kept to a minimum.
Toxicity
There are a few studies which have shown that long lasting 
treatment with lithium can provoke subclinical hypothyreosis, rare 
hyperthyreosis, or goitre [9, 20, 21]. Some side effects and toxicity 
of the lithium have been reported: nausea, diarrhoea, abdominal 
pain, polyuria, and leukocytosis. No complications directly pro-
duced by lithium were observed in the present study. We suggest 
that a relatively small dose of lithium (1.0 g/day) and short-lasting 
pre-treatment (eight days) is safe for patients and does not lead 
to the described complications.
In summary, lithium carbonate pre-treatment in patients with low 
uptake of radioiodine produced a significant increase in radioiodine 
retention in most patients and prolongation of the effective half-life 
time. The protocol presented in this report gives good results of 
radiotherapy of benign thyroid diseases in long-lasting periods and 
significantly decreases the therapeutic dose of radioiodine.
References
1. Hertz S. Treatment of thyroid disease by means of radioactive iodine. 
In: Isotopes in Biology and Medicine. University of Wisconsin Press, 
Madison 1948: 377–393.
2. Bell E, Gruenwald F. Radiojodtherapie bei benignen und malignen 
Schilddruesenerkrankungen. 1st. Springer-Verlag, Berlin Heidelberg 
2000; 7.
3. Kristensen O, Andersen HH, Pallisgaard G. Lithium carbonate in the 
treatment of thyreotoxicosis. Lancet 1976; 1: 603–605.
4. Temple R, Berman M, Carlson H.E, Robbins J, Wolff J. The use of 
lithium in Graves’ disease. Mayo Clin Proc 1972; 47: 872–878.
5. Temple R, Berman M, Robbins J, Wolff J. The use of lithium in the 
treatment of thyreotoxicosis. J Clin Invest 1972; 51: 2746–2756.
6. Bogazzi F, Bartalena L, Brogioni S et al. Comparison of radioiodine with 
radioiodine plus lithium in the treatment of Graves’ hyperthyroidism. 
J Clin Endocrin Metabol 1999; 84: 499–503.
7. Robbins J. The role of TRH and lithium in the management of thyroid 
cancer. In: Andreoli M, Monaco F, Robbins (eds). Advances in thyroid 
neoplasia. Field Educational Italia, Rome 1981; 233.
8. Gershengorn MC, Izumi M, Robbins J. Use of lithium as an adjuvant 
to radioiodine therapy in thyroid carcinoma. J Clin Endocrinol Metab 
1976; 42: 105–111.
8Nuclear Medicine Review 2011, Vol. 14, No. 1
www.nmr.viamedica.pl
Original
9. Rasmusson B, Olsen K, Rygard J. Lithium as an adjunct to 131-I-
-therapy of thyroid carcinoma. Acta Endocrinol 1983; (suppl 252): 74. 
10. Michael BE, Forouhar FA, Spencer RP. Medullary thyroid carcinoma 
with radioiodide transport. Effects of iodide-131 therapy and lithium 
administration. Clin Nucl Med 1985; 10: 274–279.
11. Sedvall G, Jansson B, Petterson U. Evidence of an altered thyroid 
function in man during treatment with lithium carbonate. Acta Psychiatr 
Scand 1969; (suppl 207): 59–66.
12. Berens SC, Bernstein RS, Robbins J, Wolff J. Antithyroid effects of 
lithium. J Clin Invest 1970; 49: 1357–1367.
13. Fyro B, Petterson U, Sedwall G. Time course for the effect of lithium 
on thyroid function in men and women. Acta Psychiat Scand 1973; 
49: 230–236.
14. Turner JG, Brownlie BEW, Rogers TGH. Lithium as an adjunct to radio-
iodine therapy for thyrotoxicosis. Lancet 1976; 1: 614–615.
15. Burrow GN, Burke WR, Himmelhoch JM, Spencer RP, Hershman JM. 
Effect of lithium on thyroid function. J Clin Endocrinol Metab 1971; 
32: 647–652.
16. Spaulding SW, Burrow GN, Bermudez F, Himmelhoch JM. The inhibit-
ing effect of lithium on thyroid hormone release in both euthyroid and 
thyreotoxic patients. J Clin Endocrinol Metab 1972; 35: 905–911.
17. Radvila A, Roost R, Burgi H, Kohler H, Studer H. Inhibition of tyreo- 
globulin biosynthesis and degradation by excess iodide synergism 
with lithium. Acta Endocrinol 1976; 81: 495–506.
18. Browline BEW, Turner JG, Oveden BM, Rogers TGH. Results of 
lithium-131I treatment of thyrotoxicosis. J Endocrinol Invest 1979; 
2: 303–304. 
19. Lombardi G, Panza N, Biondi B et al. Effects of lithium treatment on 
hypothalamic-pituitary-thyroid axis: a longitudinal study. J Endocrinol 
Invest 1993; 16: 259–263.
20. Wilson R, McKillop J H, Crocket G T et al. The effect of lithium therapy 
on parameters thought to be involved in the development of autoim-
mune thyroid disease. Clin Endocrinol 1991; 34: 357–361.
21. Barclay MI, Brownlie BEW, Turner JG, Wells JE. Lithium associated 
thyreotoxicosis: a report of 14 cases, with statistical analysis of inci-
dence. Clin Endocrinol 1994; 40: 759–764.
